Form N-PX Filer Information

Form N-PX

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD

OMB APPROVAL

OMB Number: 3235-0582

Estimated average burden hours per response: 20.8

N-PX: Filer Information

Filer CIK	0001388325
Filer CCC	********
Date of Report	06/30/2024
Are you a Registered Management Investment Company or an Institutional Manager?	Institutional Manager
Is this a LIVE or TEST Filing?	(•) LIVE ( ) TEST
Is this an electronic copy of an official filing submitted in paper format?	☐

Submission Contact Information

Name	
Phone Number	
E-mail Address	

Notification Information

Notify via Filing Website only?	☐

N-PX: Cover Page

Name and address of reporting person:

Name of reporting person (For registered management investment companies, provide exact name of registrant as specified in charter)	Novo Holdings A/S
Street 1	Tuborg Havnevej 19
Street 2	
City	Hellerup
State/Country	DENMARK
Zip code and zip code extension or foreign postal code	DK-2900
Telephone number of reporting person, including area code:	45 3527 6592

Name and address of agent for service:

Name of agent for service	
Street 1	
Street 2	
City	
State/Country	
Zip code and zip code extension or foreign postal code	

Reporting Period:	Report for the year ended June 30, 2024
SEC Investment Company Act or Form 13F File Number:	028-16231
CRD Number (if any):	
Other SEC File Number (if any):	
Legal Entity Identifier (if any):	

Report Type (check only one):

Registered Management Investment Company.

- ○ Fund Voting Report (Check here if the registered management investment company held one or more securities it was entitled to vote.)
- ○ Fund Notice Report (Check here if the registered management investment company did not hold any securities it was entitled to vote.)

Institutional Manager.

- ◉ Institutional Manager Voting Report (Check here if all proxy votes of this reporting manager are reported in this report.)
- ○ Institutional Manager Notice Report (Check here if no proxy votes are reported in this report and complete the notice report filing explanation section below)
- ○ Institutional Manager Combination Report (Check here if a portion of the proxy votes for this reporting manager are reported in this report and a portion are reported by other reporting person(s).)

Do you wish to provide explanatory information pursuant to Special Instruction B.4?:	○ Yes ◉ No
Additional information:	

N-PX: Summary - Included Managers

Number of Included Institutional Managers:	0
Included Institutional Managers:	*NONE*

N-PX: Signature Block

Reporting Person:	Novo Holdings A/S
By (Signature):	Barbara Fiorini Due
By (Printed Signature):	Barbara Fiorini Due
By (Title):	General Counsel, Finance & Operations
Date:	08/23/2024

ISSUER:	**AbCellera Biologics Inc.**
CUSIP:	**00288U106**
ISIN:	**US00288U1066**
MEETING DATE:	**June 13, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say-on-Pay.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,126,915	0	0	0	Issuer	For

ISSUER:	**Alnylam Pharmaceuticals, Inc.**
CUSIP:	**02043Q107**
ISIN:	**US02043Q1076**
MEETING DATE:	**May 16, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 2	To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the "Compensation Discussion and Analysis," executive compensation tables and accompanying narrative disclosures in this proxy statement	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			118,383	0	0	0	Issuer	For

ISSUER:	**Amicus Therapeutics, Inc.**
CUSIP:	**03152W109**

ISIN:	**US03152W1099**
MEETING DATE:	**June 6, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 4	Advisory vote on executive compensation	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			2,500,000	0	0	0	Issuer	For

ISSUER:	**Apple Inc.**
CUSIP:	**037833100**
ISIN:	**US0378331005**
MEETING DATE:	**February 28, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	Advisory vote to approve executive compensation	Section 14A say-on-pay votes	For	Against	Abstain		Issuer	For
			221,460	0	0	0		

ISSUER:	**BioMarin Pharmaceutical Inc.**
CUSIP:	**09061G101**
ISIN:	**US09061G1013**
MEETING DATE:	**May 21, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers (NEOs) as disclosed in the Proxy Statement.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			450,000	0	0	0	Issuer	For

ISSUER:	**Blueprint Medicines Corporation**
CUSIP:	**09627Y109**
ISIN:	**US09627Y1091**
MEETING DATE:	**June 12, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
			For					
Proposal 2	Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers.	Section 14A say-on-pay votes	1 Year	222,093				
			Abstain	0		0	Issuer	For
Proposal 3	Approval of a non-binding advisory vote on the compensation paid to our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			222,093	0	0	0	Issuer	For

ISSUER:	**Cable One, Inc.**
CUSIP:	**12685J105**
ISIN:	**US12685J1051**
MEETING DATE:	**May 16, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers for 2023.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			118,403	0	0	0	Issuer	For

ISSUER:	**Corcept Therapeutics Incorporated**
CUSIP:	**218352102**
ISIN:	**US2183521028**
MEETING DATE:	**May 17, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	To approve, on an advisory basis, the compensation of the Company's named execcutive officers as disclosed in the accompanying proxy statement.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			2,411,362	0	0	0	Issuer	For

ISSUER:	**Crinetics Pharmaceuticals, Inc.**
CUSIP:	**22663K107**
ISIN:	**US22663K1079**
MEETING DATE:	**June 7, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,098,600	0	0	0	Issuer	For

ISSUER:	**Insmed Incorporated**
CUSIP:	**457669307**
ISIN:	**US4576693075**
MEETING DATE:	**May 13, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 2	To conduct an advisory vote on the 2023 compensation of our named executive officers ("NEOs")	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,339,304	0	0	0	Issuer	For

ISSUER:	**Inspire Medical Systems, Inc.**
CUSIP:	**457730109**
ISIN:	**US4577301090**
MEETING DATE:	**May 2, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	Approve, on an advisory (non-binding) basis, of the compensation of our named executive officers	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			65,524	0	0	0	Issuer	For

ISSUER:	**LanzaTech Global, Inc.**
CUSIP:	**51655R101**
ISIN:	**US51655R1014**
MEETING DATE:	**June 25, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			0	0	15,814,845	0	Issuer	-

Proposal 4	To approve, on an advisory (non-binding basis), the frequency of future advisory votes to approve the compensation of our named executive officers.	Section 14A say-on-pay votes	**1 Year**	0		0	Issuer	-
			2 Years	0				
			3 Years	0				
			Abstain	15,814,845				

ISSUER:	**Marqeta, Inc.**
CUSIP:	**57142B104**
ISIN:	**US57142B1044**
MEETING DATE:	**June 13, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve a non-binding advisory resolution approving the compensation of our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			441,558	0	0	0	Issuer	For

ISSUER:	**Mirum Pharmaceuticals, Inc.**
CUSIP:	**604749101**
ISIN:	**US6047491013**
MEETING DATE:	**June 6, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,500,000	0	0	0	Issuer	For

Proposal 4	To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.	Section 14A say-on-pay votes	**1 Year**	1,500,000		0	Issuer	For
			2 Years					
			3 Years					
			Abstain	0				

ISSUER:	**Rocket Pharmaceuticals, Inc.**
CUSIP:	**77313F106**
ISIN:	**US77313F1066**
MEETING DATE:	**June 13, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,100,000	0	0	0	Issuer	For

ISSUER:	**Salesforce, Inc.**
CUSIP:	**79466L302**
ISIN:	**US79466L3024**
MEETING DATE:	**June 27, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 5	To approve, on an advisory basis, the fiscal 2024 compensation of our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			480,160	0	0	0	Issuer	For

ISSUER:	**Spero Therapeutics, Inc.**
CUSIP:	**84833T103**

ISIN:	**US84833T1034**
MEETING DATE:	**October 5, 2023**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 3	To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in this proxy statement;	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**	0	Issuer	For
			468,902	0	0			
Proposal 4	To approve by an advisory vote the frequency of holding an advisory vote on compensation of the Company's named executive officers;	Section 14A say-on-pay votes	**1 Year**	468,902		0	Issuer	For
			2 Years	0				
			3 Years	0				
			Abstain	0				

ISSUER:	**Treace Medical Concepts, Inc.**
CUSIP:	**89455T109**
ISIN:	**US89455T1097**
MEETING DATE:	**May 21, 2024**

Matters to be Voted On by Proposal Number		Category of Matter to Be Voted on (include all that are applicable)	# of Votes Cast			Number of Shares Reporting Person Loaned and did not Recall	Matter Proposed by Issuer or Security Holder	Are the votes For or Against Management's Recommendation
Proposal 2	Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			360,000	0	0	0	Issuer	For

Proposal 3	Approval, on an advisory, non-binding basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers	Section 14A say-on-pay votes	**1 Year**	360,000				
			2 Years	0		0	Issuer	For
			3 Years	0				
			Abstain	0				

ISSUER:	**Vaxcyte, Inc.**
CUSIP:	**92243G108**
ISIN:	**US92243G1085**
MEETING DATE:	**June 6, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			845,000	0	0	0	Issuer	For

ISSUER:	**Verve Therapeutics, Inc.**
CUSIP:	**92539P101**
ISIN:	**US92539P1012**
MEETING DATE:	**June 6, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	Approval, on an advisory basis, of the compensation paid to our named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			2,000,000	0	0	0	Issuer	For

Proposal 4	Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to our named executive officers.	Section 14A say-on-pay votes	**1 Year**	2,000,000		0	Issuer	For
			2 Years	0				
			3 Years	0				
			Abstain	0				

ISSUER: **Viridian Thereaputics, Inc.**
CUSIP: **92790C104**
ISIN: **US92790C1045**
MEETING DATE: **June 17, 2024**

Matters to be Voted On by Proposal Number		**Category of Matter to Be Voted on (include all that are applicable)**	**# of Votes Cast**			**Number of Shares Reporting Person Loaned and did not Recall**	**Matter Proposed by Issuer or Security Holder**	**Are the votes For or Against Management's Recommendation**
Proposal 3	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Section 14A say-on-pay votes	**For**	**Against**	**Abstain**			
			1,750,000	0	0	0	Issuer	For